Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt No Debt
IMGN's Cash to Debt is ranked higher than
96% of the 941 Companies
in the Global Biotechnology industry.

( Industry Median: 45.46 vs. IMGN: No Debt )
Ranked among companies with meaningful Cash to Debt only.
IMGN' s Cash to Debt Range Over the Past 10 Years
Min: 0.39  Med: 10000.00 Max: 50356.33
Current: No Debt
0.39
50356.33
Equity to Asset -0.19
IMGN's Equity to Asset is ranked lower than
94% of the 710 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. IMGN: -0.19 )
Ranked among companies with meaningful Equity to Asset only.
IMGN' s Equity to Asset Range Over the Past 10 Years
Min: -0.19  Med: 0.73 Max: 0.95
Current: -0.19
-0.19
0.95
F-Score: 3
Z-Score: -4.96
M-Score: 33.46
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -167.99
IMGN's Operating margin (%) is ranked lower than
59% of the 734 Companies
in the Global Biotechnology industry.

( Industry Median: -75.67 vs. IMGN: -167.99 )
Ranked among companies with meaningful Operating margin (%) only.
IMGN' s Operating margin (%) Range Over the Past 10 Years
Min: -447.86  Med: -116.56 Max: -58.16
Current: -167.99
-447.86
-58.16
Net-margin (%) -198.40
IMGN's Net-margin (%) is ranked lower than
61% of the 734 Companies
in the Global Biotechnology industry.

( Industry Median: -76.14 vs. IMGN: -198.40 )
Ranked among companies with meaningful Net-margin (%) only.
IMGN' s Net-margin (%) Range Over the Past 10 Years
Min: -448.24  Med: -116.63 Max: -49.69
Current: -198.4
-448.24
-49.69
ROE (%) -1332.22
IMGN's ROE (%) is ranked lower than
99% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: -32.22 vs. IMGN: -1332.22 )
Ranked among companies with meaningful ROE (%) only.
IMGN' s ROE (%) Range Over the Past 10 Years
Min: -109.63  Med: -58.30 Max: -22.41
Current: -1332.22
-109.63
-22.41
ROA (%) -53.59
IMGN's ROA (%) is ranked lower than
73% of the 947 Companies
in the Global Biotechnology industry.

( Industry Median: -27.48 vs. IMGN: -53.59 )
Ranked among companies with meaningful ROA (%) only.
IMGN' s ROA (%) Range Over the Past 10 Years
Min: -42.8  Med: -35.78 Max: -17.46
Current: -53.59
-42.8
-17.46
ROC (Joel Greenblatt) (%) -582.73
IMGN's ROC (Joel Greenblatt) (%) is ranked lower than
54% of the 909 Companies
in the Global Biotechnology industry.

( Industry Median: -360.35 vs. IMGN: -582.73 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
IMGN' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -651.4  Med: -323.04 Max: -150
Current: -582.73
-651.4
-150
Revenue Growth (3Y)(%) 67.10
IMGN's Revenue Growth (3Y)(%) is ranked higher than
91% of the 492 Companies
in the Global Biotechnology industry.

( Industry Median: 3.30 vs. IMGN: 67.10 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
IMGN' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -36.3  Med: 21.30 Max: 158.3
Current: 67.1
-36.3
158.3
EBITDA Growth (3Y)(%) -13.40
IMGN's EBITDA Growth (3Y)(%) is ranked lower than
63% of the 510 Companies
in the Global Biotechnology industry.

( Industry Median: -2.20 vs. IMGN: -13.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
IMGN' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -71.4  Med: 4.50 Max: 282.6
Current: -13.4
-71.4
282.6
EPS Growth (3Y)(%) -9.60
IMGN's EPS Growth (3Y)(%) is ranked lower than
56% of the 503 Companies
in the Global Biotechnology industry.

( Industry Median: -5.20 vs. IMGN: -9.60 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
IMGN' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -77.4  Med: 0.00 Max: 291.5
Current: -9.6
-77.4
291.5
» IMGN's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-07-31)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

IMGN Guru Trades in Q2 2015

PRIMECAP Management 12,867,483 sh (+2.05%)
» More
Q3 2015

IMGN Guru Trades in Q3 2015

Jim Simons 393,440 sh (New)
PRIMECAP Management 12,867,483 sh (unchged)
» More
Q4 2015

IMGN Guru Trades in Q4 2015

PRIMECAP Management 12,867,483 sh (unchged)
Jim Simons 38,040 sh (-90.33%)
» More
Q1 2016

IMGN Guru Trades in Q1 2016

Ken Fisher 244,225 sh (New)
PRIMECAP Management 12,867,483 sh (unchged)
Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with IMGN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:ADXS, NAS:CRVS, OTCPK:NICXF, NAS:ARDX, NAS:RGLS, NAS:EDGE, NAS:AKBA, NAS:BSTC, NAS:NERV, NAS:NSTG, NAS:PTI, NAS:NLNK, NAS:AGTC, NAS:VTAE, OTCPK:HZNQF, NAS:TBRA, NAS:LJPC, OTCPK:OXBDF, NAS:CNCE, NAS:RGNX » details
Traded in other countries:IMU.Germany,
Immunogen Inc is a clinical-stage biotechnology company that develops targeted anticancer therapeutics. It has developed its ADC technology to enable the creation of anticancer products.

Immunogen Inc was incorporated in 1981, in Massachusetts. The Company is a biotechnology company that develops targeted anticancer therapeutics. It has developed its ADC technology to enable the creation of anticancer products. The Company develops its own product candidates using its ADC technology. It has three wholly owned, clinical-stage anticancer compounds: mirvetuximab soravtansine, or IMGN853, coltuximab ravtansine, formerly SAR3419, and IMGN529 and have reported preclinical data for IMGN779, which expected to be next clinical-stage compound. IMGN779 is the first ADC utilizing GN technology. The compound with ADC technology is Roche's marketed product, Kadcyla (ado-trastuzumab emtansine). Eight other ADC compounds and one non-ADC, or 'naked' antibody product candidate, are in clinical testing. The Company's current partners are Amgen Inc., Bayer HealthCare (a subgroup of Bayer AG), Biotest AG, Eli Lilly and Company, or Lilly, Novartis Institutes for BioMedical Research, Inc., or Novartis, the Roche Group, Sanofi and Takeda. Its competitors include pharmaceutical companies and other biotechnology firms, Pfizer, Seattle Genetics, Roche and Bristol-Myers Squibb. Its patent portfolio had approximately 659 issued patents and approximately 645 pending patent applications all over the world. The Company is subject to a variety of foreign regulations governing clinical trials and commercial sales and distribution of its products.

Ratios

vs
industry
vs
history
P/S 4.20
IMGN's P/S is ranked higher than
73% of the 678 Companies
in the Global Biotechnology industry.

( Industry Median: 10.08 vs. IMGN: 4.20 )
Ranked among companies with meaningful P/S only.
IMGN' s P/S Range Over the Past 10 Years
Min: 2.82  Med: 15.15 Max: 97.63
Current: 4.2
2.82
97.63
Current Ratio 4.85
IMGN's Current Ratio is ranked higher than
53% of the 914 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. IMGN: 4.85 )
Ranked among companies with meaningful Current Ratio only.
IMGN' s Current Ratio Range Over the Past 10 Years
Min: 0.71  Med: 8.00 Max: 60.86
Current: 4.85
0.71
60.86
Quick Ratio 4.83
IMGN's Quick Ratio is ranked higher than
55% of the 914 Companies
in the Global Biotechnology industry.

( Industry Median: 4.21 vs. IMGN: 4.83 )
Ranked among companies with meaningful Quick Ratio only.
IMGN' s Quick Ratio Range Over the Past 10 Years
Min: 0.71  Med: 7.79 Max: 60.86
Current: 4.83
0.71
60.86
Days Sales Outstanding 0.58
IMGN's Days Sales Outstanding is ranked higher than
99% of the 611 Companies
in the Global Biotechnology industry.

( Industry Median: 63.07 vs. IMGN: 0.58 )
Ranked among companies with meaningful Days Sales Outstanding only.
IMGN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 2.88  Med: 19.78 Max: 88.26
Current: 0.58
2.88
88.26

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.28
IMGN's Price/Median PS Value is ranked higher than
89% of the 633 Companies
in the Global Biotechnology industry.

( Industry Median: 0.91 vs. IMGN: 0.28 )
Ranked among companies with meaningful Price/Median PS Value only.
IMGN' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.22  Med: 1.38 Max: 10.58
Current: 0.28
0.22
10.58
Earnings Yield (Greenblatt) (%) -116.36
IMGN's Earnings Yield (Greenblatt) (%) is ranked lower than
94% of the 912 Companies
in the Global Biotechnology industry.

( Industry Median: -8.70 vs. IMGN: -116.36 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
IMGN' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -142.78  Med: 0.00 Max: 0
Current: -116.36
-142.78
0

More Statistics

Revenue (TTM) (Mil) $65.21
EPS (TTM) $ -1.49
Beta1.98
Short Percentage of Float26.33%
52-Week Range $2.96 - 19.43
Shares Outstanding (Mil)87.08

Analyst Estimate

Jun16 Jun17 Jun18 Jun19
Revenue (Mil $) 73 58 65 153
EPS ($) -1.47 -1.64 -1.64 -0.79
EPS w/o NRI ($) -1.47 -1.64 -1.64 -0.79
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
» More Articles for NAS:IMGN

Headlines

Articles On GuruFocus.com
Cowen & Co Remains Bullish on Celldex Therapeutics Following FDA 'Breakthrough' Approval Feb 24 2015 
Gulf Resources (GURE) Soars on Natural Gas Discovery, ImmunoGen (IMGN) and Synaptics (SYNA) Surge on Jan 31 2015 
Will ImmunoGen’s Q4 Earnings Disappoint Again? Jul 30 2014 
Murray Stahl’s $6.4 Billion Horizon Kinetics Sells Out Six Companies in First Quarter May 28 2013 
ImmunoGen Inc. Reports Operating Results (10-Q) Feb 08 2011 
ImmunoGen Inc. Reports Operating Results (10-Q) Oct 29 2010 
ImmunoGen Inc. Reports Operating Results (10-K) Aug 27 2010 
ImmunoGen Inc. Reports Operating Results (10-Q) Apr 30 2010 
ImmunoGen Inc. Reports Operating Results (10-Q) Jan 29 2010 
ImmunoGen Inc. Reports Operating Results (10-Q) Nov 04 2009 

More From Other Websites
IMMUNOGEN INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct... Jun 20 2016
The 52-Week Low Club for Wednesday Jun 15 2016
ImmunoGen Announces Pricing of $100 Million Offering of 4.50% Convertible Senior Notes Due 2021 Jun 15 2016
ImmunoGen Announces Pricing of $100 Million Offering of 4.50% Convertible Senior Notes Due 2021 Jun 15 2016
The 52-Week Low Club for Tuesday Jun 14 2016
Why is ImmunoGen (IMGN) Stock Down Today? Jun 14 2016
Here’s why Microsoft, ImmunoGen, and Three Other Stocks Are Trending on Tuesday Jun 14 2016
IMMUNOGEN INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jun 13 2016
ImmunoGen Announces Proposed $100 Million Offering of Convertible Senior Notes Due 2021 Jun 13 2016
ImmunoGen Announces Proposed $100 Million Offering of Convertible Senior Notes Due 2021 Jun 13 2016
5 Breakout Stocks Under $10 Set to Soar Jun 02 2016
ETF’s with exposure to ImmunoGen, Inc. : May 24, 2016 May 24 2016
ImmunoGen Reports Efficacy and Safety Data from a 46-Patient Cohort of Mirvetuximab Soravtansine in... May 18 2016
ImmunoGen Reports Efficacy and Safety Data from a 46-Patient Cohort of Mirvetuximab Soravtansine in... May 18 2016
ASCO Could Make or Break These 7 Cancer Drug Trials May 12 2016
ImmunoGen, Inc. Announces Webcasts of Presentations at Upcoming Investor Conferences May 12 2016
ImmunoGen Reports Third Quarter Fiscal Year 2016 Financial Results and Provides Corporate Update May 12 2016
ImmunoGen Appoints Mark J. Enyedy as President and Chief Executive Officer May 12 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)